glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berdel, WE; Bieker, R; Bremer, C; Kessler, T; Kreuter, M; Mesters, RM; Padró, T; Persigehl, T; Schwöppe, C | 1 |
| Berdel, WE; Bieker, R; Bremer, C; Ebert, W; Heindel, W; Kessler, T; Kooijman, H; Matuszewski, L; Meier, N; Mesters, RM; Persigehl, T; Wall, A | 1 |
2 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Topics: Animals; Blood Flow Velocity; Endothelium, Vascular; Humans; Immunoenzyme Techniques; Integrin alphaVbeta3; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Recombinant Fusion Proteins; Thromboplastin | 2005 |
Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice.
Topics: Angiogenesis Inhibitors; Animals; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Fibrosarcoma; Injections, Intravenous; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligopeptides; Oxides; Prospective Studies; Statistics, Nonparametric | 2007 |